Loading paragraph...
Today's Biggest Stock Gainers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| BNAI | Brand Engagement Network | $1.93 | $0.73 | 60.42% | 74.2M | $5.4M | $1.18$11.80 |
| SOPA | Society Pass | $2.91 | $1.09 | 59.89% | 102.9M | $11M | $0.64$6.75 |
| GVH | Globavend | $3.75 | $1.15 | 44.23% | 3.7M | $3.3M | $2.49$364.00 |
| ORBS | Eightco | $2.08 | $0.41 | 24.63% | 20.9M | $329M | $0.98$83.12 |
| GLSI | Greenwich LifeSciences | $25.60 | $4.91 | 23.75% | 1M | $287M | $7.78$25.77 |
| SIDU | Sidus Space | $2.38 | $0.45 | 23.39% | 47.4M | $68M | $0.63$6.75 |
| WOK | Work Medical Technology Group Ltd | $3.22 | $0.47 | 17.15% | 15.9M | $2.4M | $2.66$60,000.00 |
| PALI | Palisade Bio | $2.49 | $0.34 | 15.82% | 6.8M | $320M | $0.53$2.59 |
| RGC | Regencell Bioscience | $24.49 | $3.33 | 15.74% | 420.9K | $10B | $0.09$83.60 |
| NTRB | Nutriband | $5.55 | $0.75 | 15.63% | 619.3K | $58M | $3.01$9.42 |
Related Articles
Featured Article
This Stock Soared 9,800% in 2025. Here's 1 Key Reason Why Investors Are Piling In (Spoiler: It's Regencell Bioscience Holdings (RGC) Stock)
Selena Maranjian|Nov 24, 2025
Is the stock likely to keep surging? The answer seems pretty clear.
Meet the Biotech Stock That Just Jumped 251% Higher
Cory Renauer|Oct 26, 2025
Find out what sent this typically overlooked stock through the roof.
1 Drug, 1 Mission: What Should Investors Expect for Greenwich Life Sciences?
Jia Jie Chen|Apr 21, 2021
The top-performing IPO of 2020 is a high-risk, high-reward opportunity, with one drug in its pipeline and one disease in its sights. Is it worth investing in now?
Advertisement
This Was the Top-Performing IPO in 2020
Rick Munarriz|Dec 28, 2020
A lot of buzz-generating IPOs have more than tripled in 2020, but you probably don't know the top U.S. debutante that has soared 583% this year.
Up 1,600% In 2 Days, Is It Too Late To Buy This Hot Biotech Stock?
Zhiyuan Sun|Dec 10, 2020
Greenwich LifeSciences made investors rich overnight. Is there any growth left in this breast cancer treatment developer?
